Edit

Contact Us


    Human Verification

    A Giant Leap in Liquid Biopsy

    Introducing the first comprehensive

    cfDNA and cfRNA test for clinical use

    GTC’s
    Liquid
    Trace™

    >284 cfDNA genes

    >1501 cfRNA genes

    Pan-Tumor Assay for Both Solid Tumors and Hematologic Malignancies

    GTC’s Liquid Trace™

    The Future of Precision Oncology Diagnostics is Here

    Now more patients can receive comprehensive answers about their cancer with a test that combines targeted transcriptome and cfDNA together!

    GTC’s Liquid Trace™ Test Overview

    GTC’s Liquid Trace can significantly reduce the need for bone marrow biopsies for hematology patients

    Liquid Trace Comparison table

    cfDNA Only Provides Partial Results

    Liquid Trace Overview - cfDNA Only Provides Partial Results

    Get Comprehensive Results by Combining cfRNA with cfDNA

    Liquid biopsy in its current form is dependent on cfDNA analysis; this method likewise presents multiple challenges. These include variations in DNA shedding between tumors as well as low sensitivity (especially in early-stage cancer), difficulty in detecting fusion genes (i.e., chromosomal translocations leading to the expression of chimeric mRNA from two genes), and inability to reflect the numerous biological processes that modify RNA expression levels, such as alternative splicing, stability, and allele-specific methylation. The latter limitation is critically important as recent studies have shown that RNA testing provides another level of biological information regarding the tumor and its microenvironment.

    Figure 1: Comparison of findings from cfDNA and cfRNA

    GTC’s Liquid Trace  is a pan-cancer test evaluating cfRNA and cfDNA providing highly informative data that can be used for diagnoses, evaluating the host immune response, and identifying biomarkers for predicting responses to various therapies. 

    Comparison of findings from cfDNA and cfRNA

    The Benefits of cfRNA

    RNA sequencing has proven to be more sensitive in detecting mutations in clinical studies.  This research is consistent with GTC’s findings that cfRNA has increased sensitivity over cfDNA alone.  More specifically, cfRNA allowed GTC’s Liquid Trace to detect more mutations and fusions in hematologic and solid tumor samples, which may be undetected by conventional cfDNA.

    Liquid Trace Can Detect:

    • Chromosomal Abnormalities
      – Including Gene Amplification
    • Reliable Fusion Detection
    • Gene Expression
    • Alternative Splicing
    • HRR
    • HPV/EBV
    • MRD
    • Biomarkers Discovery with AI
      – Especially for Immunotherapy